NCT03775265 2026-03-18
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
79 trialsNCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT06770582 2026-03-18
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07061964 2026-03-18
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03274687 2026-03-16
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT06171269 2026-03-04
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
University of Chicago
Phase NA Recruiting
NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04322318 2026-02-24
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Children's Oncology Group
Phase 2 Recruiting
NCT06037863 2026-02-23
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
Mayo Clinic
Phase NA Active not recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03861676 2026-02-13
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Recruiting
NCT06625034 2026-02-10
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
Mayo Clinic
Phase 3 Recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT07202247 2026-02-04
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT05946213 2026-02-02
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT07097142 2026-02-02
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT04134260 2026-01-14
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT04513717 2026-01-14
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06235697 2026-01-13
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT04175431 2025-12-18
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
University of Washington
Phase 2 Recruiting
NCT06105918 2025-12-09
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Emory University
Phase 1 Active not recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT05805371 2025-11-19
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06369610 2025-11-14
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
Mayo Clinic
Phase 2 Recruiting
NCT03987386 2025-11-12
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT04216290 2025-11-12
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03747419 2025-10-31
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03217747 2025-10-23
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06244004 2025-10-22
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT01495676 2025-10-10
GETUGV04
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Terminated
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT03889119 2025-09-15
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Hoag Memorial Hospital Presbyterian
Phase NA Active not recruiting
NCT05230251 2025-09-12
ROADSTER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2 Completed
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01492972 2025-09-04
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
Phase 3 Recruiting
NCT03570827 2025-09-03
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Phase 2 Completed
NCT01508390 2025-06-26
Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate
Boston Medical Center
Phase NA Active not recruiting
NCT04249154 2025-06-25
PROMPT
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT01342367 2025-06-10
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
University of Chicago
Phase NA Active not recruiting
NCT00945009 2025-05-31
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Children's Oncology Group
Phase 3 Active not recruiting
NCT02318771 2025-05-15
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Thomas Jefferson University
Phase 1 Completed
NCT03486197 2024-11-20
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
University of Washington
Phase 2 Terminated
NCT02184533 2024-05-28
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
Phase 1 Completed
NCT01505569 2024-02-26
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT03132922 2024-01-22
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
Phase 1 Active not recruiting
NCT06129851 2023-11-13
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
University of Kansas Medical Center
Phase 2 Not yet recruiting
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated